Group 1: Regulatory Progress - The Acarbose project has completed all professional reviews and is currently undergoing final comprehensive evaluation, with all necessary technical materials submitted as per CDE requirements [2] - The company has completed all tasks related to the new drug application and is awaiting the final review from CDE [2] Group 2: Innovation and Pipeline Strategy - The company has seen a gradual increase in available funds, enabling ongoing internal research and external collaborations to enrich the existing pipeline [2] - Future pipeline strategies will prioritize deepening focus in the neurological disease field, establishing a healthy research and development hierarchy of "one batch on the market, one batch in clinical trials, and one batch in pre-research" [2] Group 3: Commercialization Preparation - The company has completed full-process preparations for the commercialization of the new drug, including the establishment of a professional team and innovative marketing models [3] - The existing production system is adequately prepared to meet the medication needs of Alzheimer's patients, ensuring rapid market entry post-approval [3]